Catalyst
Slingshot members are tracking this event:
Phase 3 top-line data of TG-1101 (Ublituximab) and Imbruvica (GENUINE trial) for Chronic Lymphocytic Leukemia due first half 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| TGTX |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 06, 2017
Occurred Source:
http://ir.tgtherapeutics.com/releasedetail.cfm?ReleaseID=1015939
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Cll, Phase 3 Data, Tg-1101, Imbruvica, Genuine Trial, Chronic Lymphocytic Leukemia
